The role of protons in modern and biologically-guided radiotherapy

被引:14
作者
Nystrom, Hakan [1 ,2 ]
机构
[1] Skandion Clin, S-75136 Uppsala, Sweden
[2] Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark
关键词
CELL LUNG-CANCER; TUMOR-CONTROL PROBABILITY; NORMAL TISSUE; CONCURRENT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; IMRT TREATMENT; PHASE-II; RISK; DISTRIBUTIONS; OPTIMIZATION;
D O I
10.3109/0284186X.2010.498436
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the introduction of new biologically based imaging possibilities, a higher degree of individualisation and adaptation of radiotherapy will be possible. Better knowledge of the biology of the target and its sub-volumes will enable dose prescriptions tailored to the individual patients, tissues and sub-volumes. Repeated imaging during the course of treatment will in addition enable adaptation of the treatment to cope with anatomical, as well as biological changes of the patient and of the target tissues. To translate these bright future perspectives into significant improvements in clinical outcome, advanced tools to tailor the physical dose distributions are needed. The most conformal radiotherapy technique known to mankind and clinically available today is proton therapy; in particular Intensity Modulated Proton Therapy (IMPT) with active spot scanning can not only tailor the dose to the desired target, but also effectively avoid sensitive structures in the proximity of the target to a degree far better than other conformal techniques such as Intensity Modulated Radiotherapy with photons (IMRT). The development of IMPT is now mature enough for clinical introduction on a broad scale. Proton therapy is still more expensive than conventional radiotherapy, but with the present rapid increase in the number of proton facilities worldwide and new initiatives to improve efficiency, the difference in affordability will continue to decrease and in comparison with the benefits, soon diminish even further. Contrary to what is sometimes claimed, the demands for better physical dose distributions and better avoidance of non-target tissue, has never been higher. Prolonged expected survival in many groups of patients emphasises the need to reduce late toxicities. The success of concomitant systemic therapies, with their tendency to cause higher morbidity stresses even further the increased need for subtle dose-sculpting methodologies and tools. There is no contradiction between striving for better physical dose distributions and a more biologically based approach. On the contrary, physical dose distributions are the tools to which achieve a treatment that can meet the biological demands.
引用
收藏
页码:1124 / 1131
页数:8
相关论文
共 45 条
  • [1] POSTOPERATIVE PROTON RADIOTHERAPY FOR LOCALIZED AND LOCOREGIONAL BREAST CANCER: POTENTIAL FOR CLINICALLY RELEVANT IMPROVEMENTS?
    Ares, Carmen
    Khan, Shaka
    MacArtain, Anne M.
    Heuberger, Juerg
    Goitein, Gudrun
    Gruber, Guenther
    Lutters, Gerd
    Hug, Eugen B.
    Bodis, Stephan
    Lomax, Antony J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (03): : 685 - 697
  • [2] High Frequency of Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine after Induction with Gemcitabine and Carboplatin
    Arrieta, Oscar
    Gallardo-Rincon, Dolores
    Villarreal-Garza, Cynthia
    Michel, Rosa M.
    Astorga-Ramos, Alma M.
    Martinez-Barrera, Luis
    de la Garza, Jaime
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (07) : 845 - 852
  • [3] Baumann Michael, 2005, Rays, V30, P121
  • [4] Theragnostic imaging for radiation oncology: dose-painting by numbers
    Bentzen, SM
    [J]. LANCET ONCOLOGY, 2005, 6 (02) : 112 - 117
  • [5] Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: Final results of a phase II study
    Blanco, Remei
    Sole, Josep
    Montesinos, Jesus
    Mesia, Carlos
    Algara, Manuel
    Terrassa, Josefa
    Gay, Monserrat
    Domenech, Monserrat
    Bastus, Roma
    Bover, Isabel
    Nogue, Miquel
    Vadell, Catalina
    [J]. LUNG CANCER, 2008, 62 (01) : 62 - 71
  • [6] Brenner DJ, 2000, CANCER, V88, P398, DOI 10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO
  • [7] 2-V
  • [8] The use of risk estimation models for the induction of secondary cancers following radiotherapy
    Dasu, A
    Toma-Dasu, I
    Olofsson, J
    Karlsson, M
    [J]. ACTA ONCOLOGICA, 2005, 44 (04) : 339 - 347
  • [9] Treatment planning optimisation based on imaging tumour proliferation and cell density
    Dasu, Alexandru
    [J]. ACTA ONCOLOGICA, 2008, 47 (07) : 1221 - 1228
  • [10] A comparison of proton therapy and IMRT treatment plans for prostate radiotherapy
    Dowdell, S. J.
    Metcalfe, P. E.
    Morales, J. E.
    Jackson, M.
    Rosenfeld, A. B.
    [J]. AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE, 2008, 31 (04) : 325 - 331